TipRanks
Advertisement
Advertisement

FR:BIM Stock Latest News

bioMerieux price target raised to EUR 66 from EUR 64 at Morgan Stanley
The FlybioMerieux price target raised to EUR 66 from EUR 64 at Morgan Stanley
1M ago
bioMerieux price target lowered to EUR 75 from EUR 78 at Deutsche Bank
PremiumThe Fly
bioMerieux price target lowered to EUR 75 from EUR 78 at Deutsche Bank
2M ago
bioMerieux downgraded to Underweight from Equal Weight at Morgan Stanley
PremiumThe Fly
bioMerieux downgraded to Underweight from Equal Weight at Morgan Stanley
4M ago
bioMerieux price target lowered to EUR 78 from EUR 81 at Deutsche Bank
PremiumThe Fly
bioMerieux price target lowered to EUR 78 from EUR 81 at Deutsche Bank
4M ago
bioMerieux initiated with a Neutral at Piper Sandler
PremiumThe Fly
bioMerieux initiated with a Neutral at Piper Sandler
4M ago
bioMerieux downgraded to Neutral from Buy at UBS
PremiumThe FlybioMerieux downgraded to Neutral from Buy at UBS
4M ago
bioMerieux price target lowered to EUR 71.60 from EUR 120.50 at JPMorgan
Premium
The Fly
bioMerieux price target lowered to EUR 71.60 from EUR 120.50 at JPMorgan
6M ago
bioMerieux downgraded to Hold from Buy at Deutsche Bank
Premium
The Fly
bioMerieux downgraded to Hold from Buy at Deutsche Bank
6M ago
bioMerieux price target lowered to EUR 100 from EUR 108 at Morgan Stanley
PremiumThe Fly
bioMerieux price target lowered to EUR 100 from EUR 108 at Morgan Stanley
6M ago
bioMerieux price target lowered to EUR 100 from EUR 110 at Barclays
PremiumThe Fly
bioMerieux price target lowered to EUR 100 from EUR 110 at Barclays
8M ago
bioMerieux price target lowered to EUR 109 from EUR 112 at Morgan Stanley
PremiumThe Fly
bioMerieux price target lowered to EUR 109 from EUR 112 at Morgan Stanley
8M ago
bioMerieux downgraded to Neutral from Outperform at BNP Paribas
PremiumThe Fly
bioMerieux downgraded to Neutral from Outperform at BNP Paribas
9M ago
bioMerieux price target lowered to EUR 112 from EUR 113 at Morgan Stanley
PremiumThe FlybioMerieux price target lowered to EUR 112 from EUR 113 at Morgan Stanley
10M ago
bioMerieux upgraded to Neutral from Underperform at BofA
Premium
The Fly
bioMerieux upgraded to Neutral from Underperform at BofA
10M ago
bioMerieux (0RUG) Announces Q2 Dividend: Read On for Important Dates
Premium
Dividends
bioMerieux (0RUG) Announces Q2 Dividend: Read On for Important Dates
2y ago
bioMérieux’s VITEK® COMPACT PRO Gains FDA Approval to Combat Antibiotic Resistance
PremiumCompany Announcements
bioMérieux’s VITEK® COMPACT PRO Gains FDA Approval to Combat Antibiotic Resistance
2y ago
bioMérieux Prepares for May 2025 Shareholder Meeting
PremiumCompany Announcements
bioMérieux Prepares for May 2025 Shareholder Meeting
2y ago
bioMérieux Launches Innovative Diagnostic Solution for Food Safety
PremiumCompany Announcements
bioMérieux Launches Innovative Diagnostic Solution for Food Safety
2y ago
bioMérieux Gains FDA Clearance for New Gastrointestinal Panel
PremiumCompany Announcements
bioMérieux Gains FDA Clearance for New Gastrointestinal Panel
2y ago
bioMérieux to Present Strategic Growth Plans at J.P. Morgan Healthcare Conference
PremiumCompany AnnouncementsbioMérieux to Present Strategic Growth Plans at J.P. Morgan Healthcare Conference
2y ago
bioMérieux Gains FDA Clearance for Tropical Fever Test
Premium
Company Announcements
bioMérieux Gains FDA Clearance for Tropical Fever Test
2y ago
bioMérieux’s Strong Growth Continues in 2024
Premium
Company Announcements
bioMérieux’s Strong Growth Continues in 2024
2y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >